Baseline characteristics of patients at cardiac resynchronization therapy implantation
| Characteristic . | CRT-P (n = 847) . | CRT-D (n = 2722) . | Standardized difference . |
|---|---|---|---|
| Age (years), mean (SD) | 76.7 (8.89) | 69.9 (9.57) | 0.75 |
| Male sex, n (%) | 440 (52) | 1768 (65) | −0.25 |
| Non-ischaemic heart failure aetiology, n (%) | 225 (27) | 678 (25) | 0.04 |
| CRT implantation year, n (%) | |||
| 2014 | 108 (13) | 496 (18) | −0.16 |
| 2015 | 106 (13) | 466 (17) | −0.14 |
| 2016 | 123 (15) | 439 (16) | −0.05 |
| 2017 | 150 (18) | 482 (18) | 0 |
| 2018 | 178 (21) | 445 (16) | 0.12 |
| 2019 | 182 (21) | 396 (15) | 0.17 |
| Number of hospitalizations one year prior to implantation, n (%) | |||
| 0 | 40 (5) | 121 (4) | 0.01 |
| 1 | 274 (32) | 846 (31) | 0.03 |
| 2 | 222 (26) | 868 (32) | −0.13 |
| >2 | 311 (37) | 887 (33) | 0.09 |
| NYHA Class, n (%) | |||
| II | 131 (15) | 420 (15) | 0 |
| III | 548 (65) | 1712 (63) | 0.04 |
| IV | 168 (20) | 590 (22) | −0.05 |
| Heart failure specific comorbidities | |||
| Diabetes, n (%) | 272 (32) | 982 (36) | −0.08 |
| Renal dysfunction III, n (%) | 300 (35) | 749 (28) | 0.17 |
| Renal dysfunction IV, n (%) | 58 (7) | 112 (4) | 0.11 |
| Atrial fibrillation, n (%) | 497 (59) | 1105 (41) | 0.37 |
| Characteristic . | CRT-P (n = 847) . | CRT-D (n = 2722) . | Standardized difference . |
|---|---|---|---|
| Age (years), mean (SD) | 76.7 (8.89) | 69.9 (9.57) | 0.75 |
| Male sex, n (%) | 440 (52) | 1768 (65) | −0.25 |
| Non-ischaemic heart failure aetiology, n (%) | 225 (27) | 678 (25) | 0.04 |
| CRT implantation year, n (%) | |||
| 2014 | 108 (13) | 496 (18) | −0.16 |
| 2015 | 106 (13) | 466 (17) | −0.14 |
| 2016 | 123 (15) | 439 (16) | −0.05 |
| 2017 | 150 (18) | 482 (18) | 0 |
| 2018 | 178 (21) | 445 (16) | 0.12 |
| 2019 | 182 (21) | 396 (15) | 0.17 |
| Number of hospitalizations one year prior to implantation, n (%) | |||
| 0 | 40 (5) | 121 (4) | 0.01 |
| 1 | 274 (32) | 846 (31) | 0.03 |
| 2 | 222 (26) | 868 (32) | −0.13 |
| >2 | 311 (37) | 887 (33) | 0.09 |
| NYHA Class, n (%) | |||
| II | 131 (15) | 420 (15) | 0 |
| III | 548 (65) | 1712 (63) | 0.04 |
| IV | 168 (20) | 590 (22) | −0.05 |
| Heart failure specific comorbidities | |||
| Diabetes, n (%) | 272 (32) | 982 (36) | −0.08 |
| Renal dysfunction III, n (%) | 300 (35) | 749 (28) | 0.17 |
| Renal dysfunction IV, n (%) | 58 (7) | 112 (4) | 0.11 |
| Atrial fibrillation, n (%) | 497 (59) | 1105 (41) | 0.37 |
CRT-P, cardiac resynchronization therapy with pacemaker; CRT-D, cardiac resynchronization therapy with defibrillator; NYHA, New York Heart Association; SD, standard deviation.
Baseline characteristics of patients at cardiac resynchronization therapy implantation
| Characteristic . | CRT-P (n = 847) . | CRT-D (n = 2722) . | Standardized difference . |
|---|---|---|---|
| Age (years), mean (SD) | 76.7 (8.89) | 69.9 (9.57) | 0.75 |
| Male sex, n (%) | 440 (52) | 1768 (65) | −0.25 |
| Non-ischaemic heart failure aetiology, n (%) | 225 (27) | 678 (25) | 0.04 |
| CRT implantation year, n (%) | |||
| 2014 | 108 (13) | 496 (18) | −0.16 |
| 2015 | 106 (13) | 466 (17) | −0.14 |
| 2016 | 123 (15) | 439 (16) | −0.05 |
| 2017 | 150 (18) | 482 (18) | 0 |
| 2018 | 178 (21) | 445 (16) | 0.12 |
| 2019 | 182 (21) | 396 (15) | 0.17 |
| Number of hospitalizations one year prior to implantation, n (%) | |||
| 0 | 40 (5) | 121 (4) | 0.01 |
| 1 | 274 (32) | 846 (31) | 0.03 |
| 2 | 222 (26) | 868 (32) | −0.13 |
| >2 | 311 (37) | 887 (33) | 0.09 |
| NYHA Class, n (%) | |||
| II | 131 (15) | 420 (15) | 0 |
| III | 548 (65) | 1712 (63) | 0.04 |
| IV | 168 (20) | 590 (22) | −0.05 |
| Heart failure specific comorbidities | |||
| Diabetes, n (%) | 272 (32) | 982 (36) | −0.08 |
| Renal dysfunction III, n (%) | 300 (35) | 749 (28) | 0.17 |
| Renal dysfunction IV, n (%) | 58 (7) | 112 (4) | 0.11 |
| Atrial fibrillation, n (%) | 497 (59) | 1105 (41) | 0.37 |
| Characteristic . | CRT-P (n = 847) . | CRT-D (n = 2722) . | Standardized difference . |
|---|---|---|---|
| Age (years), mean (SD) | 76.7 (8.89) | 69.9 (9.57) | 0.75 |
| Male sex, n (%) | 440 (52) | 1768 (65) | −0.25 |
| Non-ischaemic heart failure aetiology, n (%) | 225 (27) | 678 (25) | 0.04 |
| CRT implantation year, n (%) | |||
| 2014 | 108 (13) | 496 (18) | −0.16 |
| 2015 | 106 (13) | 466 (17) | −0.14 |
| 2016 | 123 (15) | 439 (16) | −0.05 |
| 2017 | 150 (18) | 482 (18) | 0 |
| 2018 | 178 (21) | 445 (16) | 0.12 |
| 2019 | 182 (21) | 396 (15) | 0.17 |
| Number of hospitalizations one year prior to implantation, n (%) | |||
| 0 | 40 (5) | 121 (4) | 0.01 |
| 1 | 274 (32) | 846 (31) | 0.03 |
| 2 | 222 (26) | 868 (32) | −0.13 |
| >2 | 311 (37) | 887 (33) | 0.09 |
| NYHA Class, n (%) | |||
| II | 131 (15) | 420 (15) | 0 |
| III | 548 (65) | 1712 (63) | 0.04 |
| IV | 168 (20) | 590 (22) | −0.05 |
| Heart failure specific comorbidities | |||
| Diabetes, n (%) | 272 (32) | 982 (36) | −0.08 |
| Renal dysfunction III, n (%) | 300 (35) | 749 (28) | 0.17 |
| Renal dysfunction IV, n (%) | 58 (7) | 112 (4) | 0.11 |
| Atrial fibrillation, n (%) | 497 (59) | 1105 (41) | 0.37 |
CRT-P, cardiac resynchronization therapy with pacemaker; CRT-D, cardiac resynchronization therapy with defibrillator; NYHA, New York Heart Association; SD, standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
